Hyderabad (Telangana): Leading vaccine maker Bharat Biotech recently initiated registrations for the clinical trial of COVID-19 vaccine 'COVAXIN' at the National Institute of Virology (NIV) in Hyderabad.
After the announcement of having successfully developed India's first coronavirus vaccine, scientists at National Institute of Medical Sciences (NIMS) began the collection of samples from volunteers.
READ:| ICMR-Bharat Biotech COVID-19 vaccine trial results to be released by Aug 15
Bharat Biotech had recently received a nod for the clinical trial of COVAXIN.
It may be mentioned here that Bharat Biotech jointly developed the vaccine with ICMR and NIV, Pune from a strain of SARS-CoV-2.
However, the Drug Controller General of India-CDSCO granted permission to initiate Phase I and II human clinical trials after the company submitted results generated from preclinical studies.
READ:| Bharat Biotech aims to produce world's cheapest COVID-19 vaccine
The preclinical studies demonstrate safety and immune response. Under the preclinical trial, scientists give the vaccine to animals such as mice or monkeys to see if it produces an immune response.
However, in a pandemic situation, a vaccine may receive emergency use authorisation before getting formal approval.
Researchers around the world are developing more than 145 vaccines against the Coronavirus pandemic out of which 20 vaccines are in human trials.
READ:| Bharat Biotech’s COVID-19 vaccine first in India to receive nod for human trials
